Literature DB >> 22727345

Biomarkers of progestin therapy resistance and endometrial hyperplasia progression.

Kristen Upson1, Kimberly H Allison, Susan D Reed, Carolyn D Jordan, Katherine M Newton, Elizabeth M Swisher, Jennifer A Doherty, Rochelle L Garcia.   

Abstract

OBJECTIVE: We sought to identify biomarkers associated with progestin therapy resistance and persistence/progression of endometrial hyperplasia. STUDY
DESIGN: We performed a nested case-control study among women with complex (n = 73) and atypical (n = 41) hyperplasia treated with oral progestin, followed up 2-6 months for persistence/progression. We evaluated index endometrial protein expression for progesterone receptor isoform A, progesterone receptor isoform B (PRB), PTEN, Pax-2, and Bcl-2. Odds ratios and 95% confidence intervals (CIs) were estimated.
RESULTS: Among women with atypical hyperplasia, high PRB expression was associated with 90% decreased risk of persistence/progression (95% CI, 0.01-0.8). High expression of progesterone receptor A and PRB suggested decreased risk of persistence/progression (odds ratio, 0.1; 95% CI, 0.02-1.0). These findings were not observed among women with complex hyperplasia. No associations were found with PTEN, Pax-2, and Bcl-2 protein expression.
CONCLUSION: PRB expression shows promise as a biomarker of progestin response. Further research is warranted to understand how PRB expression may guide treatment decisions.
Copyright © 2012 Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22727345      PMCID: PMC3398620          DOI: 10.1016/j.ajog.2012.05.012

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  40 in total

1.  Joint loss of PAX2 and PTEN expression in endometrial precancers and cancer.

Authors:  Nicolas M Monte; Kaitlyn A Webster; Donna Neuberg; Gregory R Dressler; George L Mutter
Journal:  Cancer Res       Date:  2010-07-14       Impact factor: 12.701

2.  PAX2 loss by immunohistochemistry occurs early and often in endometrial hyperplasia.

Authors:  Kimberly H Allison; Kristen Upson; Susan D Reed; Carolyn D Jordan; Katherine M Newton; Jennifer Doherty; Elizabeth M Swisher; Rochelle L Garcia
Journal:  Int J Gynecol Pathol       Date:  2012-03       Impact factor: 2.762

3.  Current management of endometrial hyperplasia-a survey of United Kingdom consultant gynaecologists.

Authors:  Ioannis D Gallos; Olumide Ofinran; M Shehmar; A Coomarasamy; Janesh K Gupta
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2011-06-12       Impact factor: 2.435

4.  Molecular tools to reestablish progestin control of endometrial cancer cell proliferation.

Authors:  D Dai; N S Kumar; D M Wolf; K K Leslie
Journal:  Am J Obstet Gynecol       Date:  2001-04       Impact factor: 8.661

Review 5.  Optimal management of endometrial hyperplasia.

Authors:  D E Marsden; N F Hacker
Journal:  Best Pract Res Clin Obstet Gynaecol       Date:  2001-06       Impact factor: 5.237

6.  Apoptosis and the expression of Bax and Bcl-2 in hyperplasia and adenocarcinoma of the uterine endometrium.

Authors:  K Kokawa; T Shikone; T Otani; R Nishiyama; Y Ishii; S Yagi; M Yamoto
Journal:  Hum Reprod       Date:  2001-10       Impact factor: 6.918

7.  Down-regulated progesterone receptor A and B coinciding with successful treatment of endometrial hyperplasia by the levonorgestrel impregnated intrauterine system.

Authors:  Anne Orbo; Marit Arnes; Inger Pettersen; Kurt Larsen; Karin Hanssen; Bjorn Moe
Journal:  Acta Obstet Gynecol Scand       Date:  2010-11       Impact factor: 3.636

8.  Apoptosis and apoptosis-related factors Bcl-2, Bax, tumor necrosis factor-alpha, and NF-kappaB in human endometrial hyperplasia and carcinoma.

Authors:  Tommi E Vaskivuo; Frej Stenbäck; Juha S Tapanainen
Journal:  Cancer       Date:  2002-10-01       Impact factor: 6.860

9.  Cellular apoptosis susceptibility gene expression in endometrial carcinoma: correlation with Bcl-2, Bax, and caspase-3 expression and outcome.

Authors:  G Peiró; J Diebold; G B Baretton; R Kimmig; U Löhrs
Journal:  Int J Gynecol Pathol       Date:  2001-10       Impact factor: 2.762

10.  Bax, Bcl-2, and p53 expression in endometrial cancer.

Authors:  Noriaki Sakuragi; Alaa-eldin Salah-eldin; Hidemichi Watari; Tomoo Itoh; Shoichi Inoue; Tetsuya Moriuchi; Seiichiro Fujimoto
Journal:  Gynecol Oncol       Date:  2002-09       Impact factor: 5.482

View more
  9 in total

1.  Downregulation of FOXO1 mRNA levels predicts treatment failure in patients with endometrial pathology conservatively managed with progestin-containing intrauterine devices.

Authors:  Henry D Reyes; Matthew J Carlson; Eric J Devor; Yuping Zhang; Kristina W Thiel; Megan I Samuelson; Megan McDonald; Shujie Yang; Jean-Marie Stephan; Erica C Savage; Donghai Dai; Michael J Goodheart; Kimberly K Leslie
Journal:  Gynecol Oncol       Date:  2015-10-30       Impact factor: 5.482

2.  Endoplasmic reticulum stress in complex atypical hyperplasia as a possible predictor of occult carcinoma and progestin response.

Authors:  Katherine E Tierney; Lingyun Ji; Shannon S Dralla; Eunjeong Yoo; Annie Yessaian; Huyen Q Pham; Lynda Roman; Richard Sposto; Paulette Mhawech-Fauceglia; Yvonne G Lin
Journal:  Gynecol Oncol       Date:  2016-10-19       Impact factor: 5.482

3.  Vascular marker expression during the development of various types of gynaecological malignancy.

Authors:  Peter Urban; Miroslava Bilecova Rabajdova; Jan Varga; Peter Kruzliak; Viera Fialkovicova; Eva Durovcova; Maria Marekova
Journal:  Tumour Biol       Date:  2014-08-12

4.  Mechanism of progestin resistance in endometrial precancer/cancer through Nrf2-survivin pathway.

Authors:  Rujia Fan; Yiying Wang; Yue Wang; Li Wei; Wenxin Zheng
Journal:  Am J Transl Res       Date:  2017-03-15       Impact factor: 4.060

5.  Progestin therapy for obese women with complex atypical hyperplasia: levonorgestrel-releasing intrauterine device vs systemic therapy.

Authors:  Rachel S Mandelbaum; Marcia A Ciccone; David J Nusbaum; Mahdi Khoshchehreh; Heena Purswani; Elise B Morocco; Meghan B Smith; Shinya Matsuzaki; Christina E Dancz; Begum Ozel; Lynda D Roman; Richard J Paulson; Koji Matsuo
Journal:  Am J Obstet Gynecol       Date:  2020-01-21       Impact factor: 8.661

6.  Molecular profiling of endometrial carcinoma precursor, primary and metastatic lesions suggests different targets for treatment in obese compared to non-obese patients.

Authors:  Anna Berg; Erling A Hoivik; Siv Mjøs; Frederik Holst; Henrica M J Werner; Ingvild L Tangen; Amaro Taylor-Weiner; William J Gibson; Kanthida Kusonmano; Elisabeth Wik; Jone Trovik; Mari K Halle; Anne M Øyan; Karl-Henning Kalland; Andrew D Cherniack; Rameen Beroukhim; Ingunn Stefansson; Gordon B Mills; Camilla Krakstad; Helga B Salvesen
Journal:  Oncotarget       Date:  2015-01-20

Review 7.  Therapeutic options for management of endometrial hyperplasia.

Authors:  Vishal Chandra; Jong Joo Kim; Doris Mangiaracina Benbrook; Anila Dwivedi; Rajani Rai
Journal:  J Gynecol Oncol       Date:  2015-12-01       Impact factor: 4.401

Review 8.  New concepts for an old problem: the diagnosis of endometrial hyperplasia.

Authors:  Peter A Sanderson; Hilary O D Critchley; Alistair R W Williams; Mark J Arends; Philippa T K Saunders
Journal:  Hum Reprod Update       Date:  2017-03-01       Impact factor: 15.610

Review 9.  Efficacy of the LNG-IUS for treatment of endometrial hyperplasia and early stage endometrial cancer: Can biomarkers predict response?

Authors:  Molly Dore; Sara Filoche; Kirsty Danielson; Claire Henry
Journal:  Gynecol Oncol Rep       Date:  2021-02-19
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.